These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1901983)

  • 21. [Contribution of Pseudomonas Aeruginosa strains to infections in patients of specialistic outpatients clinics of the SP ZOZ in Nidzica].
    Pszenna M; Rokosz A; Luczak M
    Med Dosw Mikrobiol; 2005; 57(4):417-24. PubMed ID: 16773835
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)].
    Zarakolu P; Hasçelik G; Unal S
    Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cefsulodin for the treatment of Pseudomonas infections--a study comparing cefsulodin and ticarcillin.
    van der Meer JW; Matze-van der Lans A; Mattie H
    Neth J Med; 1989 Jun; 34(5-6):233-42. PubMed ID: 2671757
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evolution of the antimicrobial resistance of Pseudomonas aeruginosa in Spain: second national study (2003).
    Sánchez-Romero I; Cercenado E; Cuevas O; García-Escribano N; García-Martínez J; Bouza E;
    Rev Esp Quimioter; 2007 Jun; 20(2):222-9. PubMed ID: 17893760
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pseudomonas aeruginosa: acquired in vitro resistance to beta-lactams].
    Thabaut A; Meyran M
    Pathol Biol (Paris); 1983 May; 31(5):387-91. PubMed ID: 6413939
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antimicrobial use and Pseudomonas aeruginosa susceptibility profile in a cystic fibrosis centre.
    Manno G; Cruciani M; Romano L; Scapolan S; Mentasti M; Lorini R; Minicucci L
    Int J Antimicrob Agents; 2005 Mar; 25(3):193-7. PubMed ID: 15737511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
    Joo EJ; Kang CI; Ha YE; Kang SJ; Park SY; Chung DR; Peck KR; Lee NY; Song JH
    Microb Drug Resist; 2011 Jun; 17(2):305-12. PubMed ID: 21381966
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Susceptibility of Pseudomonas aeruginosa to beta-lactam antibiotics.
    Philippon A
    Chemioterapia; 1985 Dec; 4(6):424-8. PubMed ID: 3938346
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emergence of highly antibiotic-resistant Pseudomonas aeruginosa in relation to duration of empirical antipseudomonal antibiotic treatment.
    Philippe E; Weiss M; Shultz JM; Yeomans F; Ehrenkranz NJ
    Clin Perform Qual Health Care; 1999; 7(2):83-7. PubMed ID: 10747571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial therapy and control of multidrug-resistant Pseudomonas aeruginosa bacteremia in a teaching hospital in Taiwan.
    Leung CH; Wang NY; Liu CP; Weng LC; Hsieh FC; Lee CM
    J Microbiol Immunol Infect; 2008 Dec; 41(6):491-8. PubMed ID: 19255693
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [E-test to study small inhibitor concentrations, bacterial diversity and to identify presumptively beta-lactamases in strains of Pseudomonas aeruginosa and Acinetobacter baumannii associated with +nosocomial infections].
    Triantafilo V; Fica A; Silva M; Thompson L
    Rev Med Chil; 1997 Feb; 125(2):149-60. PubMed ID: 9430934
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vitro activity of piperacillin, ticarcillin, mezlocillin, ticarcillin-clavulanic acid, aztreonam, ceftazidime, azlocillin, cefoperazone, and thienamycin against Pseudomonas aeruginosa.
    Greenberg RN; Bollinger MR; Alivisatos MR
    Clin Ther; 1986; 8(6):655-7. PubMed ID: 3098426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nosocomial outbreak by imipenem-resistant metallo-beta-lactamase-producing Pseudomonas aeruginosa in an adult intensive care unit in a Brazilian teaching hospital.
    Cezário RC; Duarte De Morais L; Ferreira JC; Costa-Pinto RM; da Costa Darini AL; Gontijo-Filho PP
    Enferm Infecc Microbiol Clin; 2009 May; 27(5):269-74. PubMed ID: 19386392
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PER-1- and OXA-10-like beta-lactamases in ceftazidime-resistant Pseudomonas aeruginosa isolates from intensive care unit patients in Istanbul, Turkey.
    Aktaş Z; Poirel L; Salcioğlu M; Ozcan PE; Midilli K; Bal C; Anğ O; Nordmann P
    Clin Microbiol Infect; 2005 Mar; 11(3):193-8. PubMed ID: 15715716
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Susceptibility patterns and cross-resistance of antibiotics against Pseudomonas aeruginosa isolated from burn patients in the South of Iran.
    Japoni A; Alborzi A; Kalani M; Nasiri J; Hayati M; Farshad S
    Burns; 2006 May; 32(3):343-7. PubMed ID: 16527415
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial resistance among clinical isolates of Pseudomonas aeruginosa from patients in a teaching hospital, Riyadh, Saudi Arabia, 2001-2005.
    Babay HA
    Jpn J Infect Dis; 2007 May; 60(2-3):123-5. PubMed ID: 17515646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [In vitro study of the sensitivity to antibiotics of 213 Pseudomonas aeruginosa strains isolated in an intensive care unit of the Sfax Hospital (Tunisia)].
    Karray H; Hammami A; Mahjoubi F; Bouaziz M; Damak J; Jeddi HM
    Pathol Biol (Paris); 1993 Apr; 41(4):307-12. PubMed ID: 8233627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Spread in hospital units of a Pseudomonas aeruginosa phenotype producing a beta-lactamase highly inducible by clavulanic acid in vitro].
    Buisson Y; Nizou JY; Talarmin A; Meyran M
    Pathol Biol (Paris); 1992 May; 40(5):566-72. PubMed ID: 1495845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Resistance to antibiotic treatment produced in a model of experimental Pseudomonas aeruginosa peritonitis].
    Froidefond S; Saivin S; Lemozy J; Marchou B; Auvergnat JC; Dabernat H
    Pathol Biol (Paris); 1992 May; 40(5):573-82. PubMed ID: 1495846
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of ceftazidime restriction on gram-negative bacterial resistance in an intensive care unit.
    Brahmi N; Blel Y; Kouraichi N; Lahdhiri S; Thabet H; Hedhili A; Amamou M
    J Infect Chemother; 2006 Aug; 12(4):190-4. PubMed ID: 16944257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.